Placebo only

DRUG3 trials

Sponsors

GlaxoSmithKline, Wayne State University, Tris Pharma, Inc.

Conditions

Acute PainPTSDPost Traumatic Stress DisorderPulmonary Disease, Chronic Obstructive

Phase 1

Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery

Not yet recruitingNCT06222268

Wayne State UniversityPost Traumatic Stress Disorder, PTSD

Start: 2026-03-01End: 2031-09-01Target: 280Updated: 2026-02-03

Phase 3

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD

CompletedNCT01313637

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2011-03-01End: 2012-04-19Updated: 2018-01-29

A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy

CompletedNCT06423703

Tris Pharma, Inc.Acute Pain

Start: 2024-07-18End: 2025-01-31Updated: 2026-01-26

Related Papers

Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis.

2019-03-269 citations

A meta-analysis of four randomized clinical trials to confirm the reliability and responsiveness of the Shortness of Breath with Daily Activities (SOBDA) questionnaire in chronic obstructive pulmonary disease.

2015-10-315 citations

Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.

2014-05-01122 citations